Patient description: The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment. She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Migraine Subject Is male or female, in otherwise good health, 18 to 65 years of age Has history of frequent episodic migraine (6-14 migraine days per month) (with or without aura) according to the 2nd Edition of The International Headache Classification (ICHD-2) for at least 3 months. (Stage 2-3 frequent transforming migraine) Had onset of migraine before age 50 Is able to differentiate migraine from any other headache they may experience (e.g., tension-type headache) Has stable history of headache at least 3 months prior to screening Is not currently taking a migraine preventive or has been taking preventive for at least 30 days prior to screening and agrees to not start, stop, or change medication and/or dosage during the study period Has at least 50% of migraine attacks beginning at mild severity If female of childbearing potential, has a negative urine pregnancy test at Visits 1-5 and uses, or agrees to use, for the duration of the study, a medically acceptable form of contraception as determined by the investigator. 1. Complete abstinence from intercourse from 2 weeks prior to administration of study drug throughout the study, and for a time interval after completion or premature discontinuation from the study to account for elimination of the study drug (a minimum of 7 days); or, 2. Surgically sterile (hysterectomy or tubal ligation or otherwise incapable of pregnancy); or, 3. Sterilization of male partner; or, 4. Intrauterine device with published data showing lowest expected failure rate is less than 1% per year; or, 5. Double barrier method (i.e., 2 physical barriers OR 1 physical barrier plus spermicide) for a least 1 month prior to Visit 1 and throughout study; or, 6. Hormonal contraceptives for at least 3 months prior to Visit 1 and throughout study Had 6 or more migraine treatment days in 1 month prior to Visit 2  Subject Is unable to understand the study requirements, the informed consent, or complete headache records as required per protocol Is pregnant, actively trying to become pregnant, or breast-feeding Has experienced the following migraine variants: basilar migraine, aura without headache, familial hemiplegic migraine, complicated migraine, ophthalmoplegic migraine and retinal migraine Has a history of Medication Overuse Headache in the 3 months prior to study enrollment or during the baseline phase Has history of acute migraine treatment greater than14 days per month in 3 months prior to screening Has abused, in the opinion of the Investigator, any of the following drugs, currently or within the past 1 year: 1. opioids 2. alcohol 3. barbiturates 4. benzodiazepine 5. cocaine Has history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study Has an unstable neurological condition or a significantly abnormal neurological examination with focal signs or signs of increased intracranial pressure Suffers from cardiovascular disease (ischemic heart disease, including angina pectoris, myocardial infarction, documented silent ischemia, or with Prinzmetal's angina); has symptoms of ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease or Raynaud's Syndrome; has uncontrolled hypertension (≥140/90 millimeters of mercury (mmHg) in 2 out of 3 blood pressure (BP) measurements at screening); has electrocardiogram (ECG) results outside normal limits for clinically stable patients as judged by the investigator